Koninklijke DSM NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Koninklijke DSM NV's DSM Pharmaceutical Products And Almac Sign Collaboration Agreement In Biocatalysis
DSM Pharmaceutical Products, the custom manufacturing and technology business of Koninklijke DSM NV, announced that it has signed a collaboration agreement with the Almac Group Ltd. (UK) in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry. The agreement grants both parties access to their enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients (APIs). Almac's expertise in rapid enzyme identification, scale-up and implementation into early phase projects complements DSM's experience and track record of over 30 commercial manufacturing bioprocesses run on a multi-ton scale. This will give customers of either party access to enzyme expertise and assets resulting in cost-effective, green processing at all phases of development from preclinical to commercial manufacturing scale. This collaboration will also enable Almac to offer its customers a preferred partner for large-scale production.
Latest Developments for Koninklijke DSM NV
- Koninklijke DSM NV proposes fiscal year 2013 dividend
- Koninklijke DSM NV gives FY 2013 outlook in line with analysts' estimates
- Koninklijke DSM NV and JLL Create Pharma Services Company In USD2.6 Billion Transaction; Global CDMO Company Combines DSM Pharmaceutical Products And Patheon Inc
- Koninklijke DSM NV Updates Its FY 2013 EBITDA Guidance Above Analysts' Estimates
- Share this
- Digg this